Bladder cancer laboratory findings: Difference between revisions
No edit summary |
|||
| Line 15: | Line 15: | ||
{{WS}} | {{WS}} | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Revision as of 16:48, 26 August 2012
|
Bladder cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Bladder cancer laboratory findings On the Web |
|
American Roentgen Ray Society Images of Bladder cancer laboratory findings |
|
Risk calculators and risk factors for Bladder cancer laboratory findings |
Steven C. Campbell, M.D., Ph.D.
Overview
The gold standard of diagnosing bladder cancer is urine cytology and transurethral (through the urethra) cystoscopy. Urine cytology can be obtained in voided urine or at the time of the cystoscopy ("bladder washing"). Cytology is very specific (a positive result is highly indicative of bladder cancer) but suffers from low sensitivity (a negative result does not exclude the diagnosis of cancer). There are newer urine bound markers for the diagnosis of bladder cancer. These markers are more sensitive but not as specific as urine cytology. They are much more expensive as well. Many patients with a history, signs, and symptoms suspicious for bladder cancer are referred to a urologist or other physician trained in cystoscopy, a procedure in which a flexible tube bearing a camera and various instruments is introduced into the bladder through the urethra. Suspicious lesions may be biopsied and sent for pathologic analysis.